Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
HOUSE DUST MITES (HDM) ALLERGY SHOT MARKET
MARKET INSIGHTS
Global House Dust Mites (HDM) Allergy Shot market was valued at USD 1.65 billion in 2024. The market is projected to grow from USD 1.78 billion in 2025 to USD 3.02 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period.
House Dust Mite (HDM) allergy shots, clinically known as subcutaneous immunotherapy (SCIT), are a form of long-term treatment designed to reduce sensitivity to allergens. These injections contain purified allergen extracts from dust mites, such as Dermatophagoides pteronyssinus and Dermatophagoides farinae, which are the most common species triggering allergic reactions. The therapy works by administering gradually increasing doses of the allergen to desensitize the patient's immune system, thereby modifying the underlying allergic disease rather than just treating symptoms.
The market growth is primarily driven by the rising global prevalence of allergic rhinitis and asthma, with dust mites being a leading trigger. It is estimated that up to 85% of asthmatics are sensitive to dust mites, creating a significant addressable patient population. Furthermore, increasing awareness and improved diagnostic techniques are leading to higher diagnosis rates. Recent developments include the advancement of standardized allergen extracts for more consistent efficacy, and strategic initiatives by key players. For instance, ALK-Abell continues to invest in clinical trials for its SLIT-tablet and SCIT formulations, strengthening its market position. Stallergenes Greer, HAL Allergy Group, and DBV Technologies are other key players operating in this competitive market with diverse product portfolios.
Rising Global Prevalence of Dust Mite Allergies
The increase in urbanization, time spent indoors, and changes in building standards have contributed to a higher prevalence of house dust mite (HDM) allergies, which are among the most common triggers for perennial allergic rhinitis and asthma. An estimated 10-20% of the global population is sensitized to HDM allergens, creating a substantial and growing patient pool seeking long-term management solutions beyond symptomatic relief.
Growing Preference for Allergen Immunotherapy (AIT)
There is a clear shift in clinical practice towards recommending allergen immunotherapy (AIT), including allergy shots (subcutaneous immunotherapy or SCIT), for HDM allergies. This is driven by robust clinical evidence demonstrating its efficacy in modifying the underlying disease course, providing long-term relief even after treatment cessation, which is a significant advantage over daily pharmacotherapy.
Advancements in standardized, high-quality allergen extracts have improved the safety and consistency of HDM allergy shots, increasing physician and patient confidence.
Furthermore, growing patient awareness and education about the benefits of a disease-modifying treatment, rather than just managing symptoms, are propelling demand. Healthcare providers are increasingly positioned to offer AIT as a primary long-term strategy for appropriate candidates.
MARKET CHALLENGES
High Treatment Burden and Patient Adherence
The significant time commitment required for HDM allergy shots is a major challenge. The treatment protocol involves a lengthy build-up phase with frequent weekly or bi-weekly injections at a clinical facility, followed by a multi-year maintenance phase. This demands a high level of patient dedication and can lead to substantial dropout rates, impacting long-term efficacy and market revenue potential.
Other Challenges
Risk of Adverse Reactions
Despite being generally safe, SCIT carries a risk of systemic reactions, including anaphylaxis, albeit rare. This necessitates administration in a medically supervised setting with resuscitation equipment available, limiting its accessibility and increasing the overall cost and complexity of treatment.
Regulatory Hurdles and Reimbursement Variability
The approval process for allergen extracts can be complex and varies by region, potentially delaying market entry for new or improved formulations. Additionally, reimbursement policies for AIT differ significantly across healthcare systems and payers, creating uncertainty and access barriers for patients.
Competition from Sublingual Immunotherapy (SLIT)
The growth of the HDM allergy shot market is restrained by the increasing adoption of sublingual immunotherapy (SLIT). SLIT tablets and drops for HDM allergy offer the advantage of at-home administration after the first dose, presenting a more convenient and less time-consuming alternative for many patients. This convenience factor is a significant competitive pressure on the traditional SCIT market.
Cost and Resource Intensity
The requirement for in-clinic administration makes SCIT a resource-intensive therapy for healthcare providers, requiring dedicated space, staff, and time. These factors contribute to the high overall cost of treatment, which can be a restraint for both healthcare budgets and patients in regions with limited insurance coverage or high out-of-pocket expenses.
Development of Adjuvant and Ultra-Rush Protocols
There is significant opportunity in the development of novel adjuvants and accelerated (ultra-rush) build-up protocols for HDM SCIT. These innovations aim to enhance the immune response, potentially shortening the overall treatment duration and reducing the number of required clinic visits. This directly addresses the primary challenge of treatment burden and could improve patient adherence rates significantly.
Expansion in Emerging Economies
As allergy awareness increases and healthcare infrastructure improves in emerging economies across Asia-Pacific and Latin America, there is a substantial untapped market for HDM AIT. The rising middle-class population with growing disposable income and increasing diagnosis rates of allergic diseases presents a major growth frontier for market players willing to establish a presence and navigate local regulatory landscapes.
Personalized Medicine and Biomarker Development
Research into biomarkers that predict treatment response to HDM SCIT represents a future opportunity. The ability to identify optimal candidates for allergy shots would improve success rates, justify the treatment's cost and commitment, and allow for more personalized treatment strategies, thereby strengthening the value proposition of SCIT in the allergist's toolkit.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Intramuscular Injection represents the cornerstone of HDM allergy shot administration due to its well-established safety profile and proven efficacy in clinical practice. This method is favored by healthcare providers for its controlled delivery and reliable absorption into the systemic circulation, which is critical for achieving long-term immune tolerance. The familiarity and extensive clinical experience with intramuscular routes contribute to their dominant position in treatment protocols, with ongoing research focused on optimizing dosing schedules to improve patient convenience. |
| By Application |
|
Hospitals are the principal setting for the administration of HDM allergy shots, driven by their comprehensive infrastructure for managing potential anaphylactic reactions and conducting initial dose escalation phases under strict medical supervision. These institutions provide the necessary environment for handling complex cases and patients with severe allergic histories, ensuring adherence to stringent safety protocols. The trend towards specialized allergy centers within hospitals further solidifies their leading role, offering integrated care from diagnosis through long-term maintenance therapy. |
| By End User |
|
Adults constitute the primary end-user group for HDM allergy shots, largely because this demographic typically has a longer history of persistent allergic symptoms that have not been adequately controlled by medications. Adults are often more motivated to pursue a long-term solution like immunotherapy and are better equipped to adhere to the demanding multi-year treatment schedules. The management of treatment in adults is considered more straightforward regarding consent and compliance, making this segment the main focus for healthcare providers and manufacturers developing new therapeutic formulations. |
| By Treatment Regimen |
|
Maintenance Phase is the leading segment in terms of treatment duration and recurring demand, as it represents the long-term period where patients receive standardized doses at regular intervals to sustain immune tolerance. This phase is critical for the commercial success of HDM allergy shots, as it ensures ongoing patient engagement and consistent revenue streams for manufacturers and providers. The focus within this segment is on improving patient adherence through innovations that enhance convenience and reduce the frequency of clinic visits, which is a key driver for market growth. |
| By Distribution Channel |
|
Hospital Pharmacies represent the dominant distribution channel, primarily because HDM allergy shots are specialized biologics that often require controlled storage conditions and are administered on-site by medical professionals. This channel ensures product integrity from manufacturer to patient and aligns with the treatment protocols that mandate supervision. The integrated nature of procurement and administration within hospital settings provides a seamless supply chain, reducing logistical complexities and ensuring that patients have reliable access to their prescribed immunotherapy treatments. |
An Oligopolistic Market Led by Pioneers in Allergy Immunotherapy
The global House Dust Mites (HDM) Allergy Shot market is characterized by the dominance of a few established players with deep expertise in allergy immunotherapy. Stallergenes Greer and ALK-Abell are recognized as global leaders, collectively holding a significant revenue share. Their market leadership is built on extensive portfolios of sublingual and subcutaneous immunotherapy products, strong R&D pipelines, and well-established global distribution networks. These companies focus on developing targeted therapies with improved safety profiles and enhanced patient convenience, driving market growth through strategic expansions and clinical advancements.
Beyond the top tier, the market includes several other significant players that contribute to the competitive dynamics through specialized approaches. Companies like Allergy Therapeutics, HAL Allergy Group, and DBV Technologies are carving out important niches. For instance, DBV Technologies is pioneering epicutaneous immunotherapy, while companies like Aimmune Therapeutics (now part of Nestl Health Science) and Biomay AG focus on innovative vaccine platforms. This competitive environment is further enriched by regional specialists and smaller biotechnology firms dedicated to advancing novel HDM allergy treatments, ensuring a dynamic and innovative market landscape.
List of Key House Dust Mites (HDM) Allergy Shot Companies ProfiledStallergenes Greer
Allergy Therapeutics
DBV Technologies
Biomay AG
Anergis
Arrayit Corporation
Merck KGaA
Leti Pharma
Circassia Pharmaceuticals (a subsidiary of AstraZeneca)
Wolw Pharma
The global House Dust Mites (HDM) Allergy Shot market is demonstrating robust expansion, propelled by an increasing global prevalence of allergic rhinitis and asthma triggered by dust mite allergens. The market was valued at a significant figure in 2024 and is projected to grow substantially by 2032. This steady growth trajectory underscores the persistent demand for effective long-term management solutions beyond symptomatic relief offered by antihistamines.
Other TrendsTechnological Advancements and Route of Administration
Innovation in administration routes is a key trend, with the Intramuscular Injection segment expected to witness significant growth with a notable CAGR over the forecast period. This growth is attributed to its established efficacy and widespread adoption in clinical settings. Concurrently, research into alternative delivery methods, including sublingual immunotherapy, is influencing market dynamics and competitive strategies.
Competitive Landscape and Strategic Consolidation
The market is characterized by the presence of established players such as Stallergenes Greer, ALK Abello, and Allergy Therapeutics, which collectively held a major share of the global revenue in 2024. The competitive environment is further shaped by ongoing research and development efforts, mergers, and acquisitions as companies strive to enhance their product portfolios and expand their geographic footprint to capitalize on emerging opportunities.
Regional Market DynamicsThe United States represents a major market for HDM allergy shots. However, the Asia-Pacific region, particularly China, is projected to be a high-growth market, reaching a considerable market size by 2032. This shift is driven by rising healthcare expenditure, increasing awareness of allergy diagnostics, and a growing patient population in densely populated areas. Europe also continues to be a significant contributor to the global market revenue.
Regional Analysis: House Dust Mites (HDM) Allergy Shot MarketEurope
Europe represents a mature and significant market for HDM allergy shots, characterized by a high prevalence of allergic diseases and strong national healthcare systems. Countries like Germany, France, and the United Kingdom are key contributors, with established guidelines for the diagnosis and management of allergies. The market dynamics are influenced by a growing emphasis on sublingual immunotherapy as an alternative, yet subcutaneous shots remain a cornerstone of treatment, especially for more severe cases. Environmental factors, including older housing stock and varying climates, contribute to regional differences in HDM exposure. The European regulatory landscape, guided by the European Medicines Agency, ensures high standards for allergen product quality and safety.
Asia-Pacific
The Asia-Pacific region is identified as the fastest-growing market for HDM allergy shots, driven by increasing urbanization, rising disposable incomes, and a growing awareness of allergic diseases. Countries such as Japan, Australia, and South Korea have well-developed markets, while emerging economies like China and India present substantial growth potential due to their vast populations and increasing healthcare expenditure. The humid and warm climates in many parts of the region are highly conducive to dust mite proliferation, leading to a large and growing patient pool. However, market growth is tempered by challenges such as limited access to specialist care in rural areas and varying levels of reimbursement policies across different countries.
South America
The South American market for HDM allergy shots is evolving, with Brazil and Argentina being the primary markets. The region experiences a high prevalence of allergic sensitization to house dust mites, attributed to tropical and subtropical climates that favor mite growth. Market development is supported by improving healthcare infrastructure and a gradual increase in the number of trained allergists. However, the market faces constraints, including economic volatility affecting healthcare spending and a stronger initial focus on pharmaceutical symptomatic treatments rather than long-term immunotherapy. Efforts are underway to increase physician and patient education about the benefits of allergy shots.
Middle East & Africa
This region exhibits a diverse and developing market for HDM allergy shots. The Gulf Cooperation Council countries, with their higher healthcare spending, show more advanced adoption, whereas other parts of the region are still in nascent stages. The hot and often humid climate in coastal areas contributes to a significant burden of HDM allergies. A key market dynamic is the increasing investment in healthcare infrastructure and a growing focus on specialized medical care. Challenges include limited awareness about immunotherapy options among the general population and a scarcity of allergy specialists in many areas, which currently restricts market penetration compared to more developed regions.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Healthcare providers and hospital systems
Pharmaceutical and biotechnology companies
Allergy and immunology specialists
Research institutions and diagnostic labs
Investors, consultants, and policy makers
-> Global House Dust Mites (HDM) Allergy Shot market was valued at USD 1.65 billion in 2024 and is projected to reach USD 3.02 billion by 2032.
-> Key players include Stallergenes Greer, ALK Abello, HAL Allergy Group, DBV Technologies, and Allergy Therapeutics, among others.
-> The market is expected to exhibit a compound annual growth rate (CAGR) of 7.8% during 2025-2032.
-> Key growth drivers include rising prevalence of allergic diseases, improved diagnostic techniques, and increasing awareness of immunotherapy options.
-> The market is segmented into Intramuscular Injection and Intravenous Injection, with intramuscular injection holding significant market share.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates